drugset / Trial / NCT01957579
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.
Timeline
- Start
- 2011-05-25
- Primary completion
- 2015-09-15
- Completion
- 2015-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inebilizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |